Latest News

• Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialization of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in the Chinese market.
• The agreement focuses on treating chronic obstructive pulmonary disease (COPD).
• SUP will handle regulatory approvals for selling Tiotropium DPI in China.
• Lupin will be the marketing authorization holder and responsible for manufacturing the product.
• Fabrice Egros, President of Corporate Development, Lupin, stated that the partnership demonstrates their commitment to developing critical products for respiratory diseases and establishing leadership in the global respiratory health sector.
• Wang Li, President of SUP, mentioned that the collaboration will strengthen their synergy in respiratory care and aim to make significant breakthroughs in respiratory disease treatment in China.

Global pharma major Lupin Limited (Lupin) will present data from its Phase 1a clinical trial evaluating LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, from May 30 to June 3, 2025.

• The presentation, titled "A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors," will be featured in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session.
• It can be viewed at Poster Board #422 on June 2, 2025, from 1:30 pm to 4:30 pm (CDT).
• Key findings from the study indicate that LNP7457 is generally safe and well tolerated in patients with advanced or metastatic solid tumors, exhibiting a desirable PK/PD profile with no impact of food on pharmacokinetics.
• The maximum tolerated dose and recommended phase 2 dose were determined based on safety, efficacy, and PK/PD data, aligning with preclinical findings and the known safety profile of PRMT5 inhibitors.
• Vinita Gupta, CEO, expressed delight in sharing the initial results from the Phase I study of their PRMT5 Inhibitor, a novel epigenetic onco-therapeutic targeted for monotherapy. She emphasized Lupin's commitment to innovation and advancing cutting-edge science to offer meaningful therapeutic options for patients with difficult-to-treat cancers.
• Lupin will continue to study the efficacy of LNP7457 in its phase 1b trial in India and explore its potential for treatment of cancers with significant unmet medical needs.

• Global Pharma major Lupin Limited announced on 26 May 2025 that it has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America.
• The agreement is for the commercialization of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.
• Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations, and commercialization of Ranibizumab in LATAM, while Lupin will be responsible for its manufacturing.
• Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A).
• Its indications include the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularization (mCNV).
• Dr. Cyrus Karkaria, President Biotechnology, Lupin, commented that the partnership with SteinCares underscores Lupin's commitment to providing innovative, high-quality healthcare solutions and aims to transform the landscape of retinal care in Latin America.
• Sebastián Katz, Chief Strategy Officer at SteinCares, stated that this partnership strengthens their portfolio and reinforces SteinCares’ position as a biosimilar powerhouse in Latin America, noting their consistent ability to be first to market products from highly regulated markets.

Lupin Limited announced on May 23, 2025, that its wholly-owned US subsidiary, Lupin Inc. USA (LI), converted a loan of USD 41 million and outstanding interest of USD 3.3 million, totaling USD 44.3 million, into equity in Lupin Oncology Inc., USA (LOI). This conversion has resulted in LOI becoming a step-down subsidiary of Lupin Limited.

Key details of the transaction:

• Lupin Oncology Inc. (LOI) was incorporated on March 15, 2021, under the laws of Delaware, USA.
• Prior to this conversion, LOI was a direct subsidiary of Lupin Limited, with the company holding 99.33% equity.
• Post-conversion, the revised shareholding structure in LOI is: LI holds 81.12%, Lupin Limited holds 18.75%, and other shareholders hold 0.13%. The combined equity stake of Lupin Limited and LI in LOI is 99.87%.
• LOI's financial details as of March 31, 2025, show its Turnover as NIL and Net Worth as USD 7.0 million.
• LOI operates in the Pharmaceuticals industry and is engaged in the development/co-development and commercialization of various oncology products in the US.
• The transaction is classified as a related party transaction but was conducted at arm's length.
• No governmental or regulatory approvals were required for this transaction, and it has already been completed.

Mumbai, Delhi, May 20, 2025: Global pharma major Lupin Limited announced its plan to use Honeywell’s Solstice® Air (HFO-1234ze cGMP) propellant to transform respiratory care through the development of next-generation inhalers. These inhalers are designed for patients with asthma and chronic obstructive pulmonary disease (COPD).

Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a significant step forward in helping to reduce carbon emissions. Lupin intends to become the first pharmaceutical company in India to use Honeywell’s Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs).

Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%. By investigating the use of this innovative, non-flammable propellant, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options.

• Vinita Gupta, CEO Lupin, stated, “Lupin’s partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact.”
• Jeff Dormo, a president in Honeywell’s Energy and Sustainability Solutions business, commented, “Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions.”

The terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin.